DR. GONUL VELICELEBI'S `DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE DRUGS FOR CNS DISEASES` ENTITLED PRESENTATION
DR. GONUL VELICELEBI'S `DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE DRUGS FOR CNS DISEASES` ENTITLED PRESENTATION
Dr. Gonul Velicelebi, founder and CEO of Camino Pharma, San Diego, CA, delivered a speech titled "Discovery and Development of Small Molecule Drugs for CNS Diseases" on 5th of October 2018 at IBG. In her speech, she talked about functionally modulators of metabotropic glutamate receptors (mGlus), which are a family of G protein-coupled receptors and are involved in the modulation of synaptic transmission and neuronal excitability throughout the central nervous system (CNS). She stated the importance of these modulators and how they can be used as potential drugs for treating multiple CNS disorders. Furthermore, she shared information about discovery and optimization of distinct chemical scaffolds that either act as selective and potent positive allosteric modulators or negative allosteric modulators of mGlu2 receptors.
